Pricing Log in Create free account
Saturday 17 October 2026 Export GRCE’s income statement to Excel — free account

Grace Therapeutics, Inc.

GRCE Healthcare Biotechnology

In the quarter to June 2026, EPS fell 333.3% and free cash flow fell 78.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.

1.89 0.06 −3.08%
Market cap
$41.0M
P/E
0.0×
Fwd P/E
−4.4×
Dividend yield
—
F-score
n/a
Altman Z
3.31
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.47
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — 1 4 2
Sell — — — — — — — — — — — —
Insider Ownership 0.93%

Capital & Financial Ratios $m

Market Cap 41.02
Revenue 0.20
Net Income (20.22)
Free Cash Flow (10.29)
Net Debt (13.76)
Current Ratio 11.47 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (4.43) (negative: loss-making)
P/S ratio 163.45 (above 10: high)
P/B ratio 0.68
Past 5Y EPS Growth —
This Y EPS Growth (43.62%) (below 0%: weak)
Next Y EPS Growth 31.11% (at or above 15%: strong)
Next Y revenue growth 400,769,071.30% (at or above 10%: strong)
Next 5Y EPS Growth 53.39% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 109×, against a ten-year median of 194×; over the ten years it ranged from −67.2× in 2022 to 24,193× in 2019.
P/S against its own 10 years 20.83%
10-year low 10-year high
P/B against its own 10 years 36.40%
10-year low 10-year high
EV/Sales against its own 10 years 26.00%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 23 22 17 14
Receivables 1 0 0 0
Inventory — — — —
Other — — — —
24 23 17 14
2024 2025 2026 Q'26
Payables 2 2 2 1
ST’ Debt — — — —
Other — — — —
2 2 2 1

Compound Annual Growth %

10y 5y 3y
Sales — (22.91%) 89.29%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 14.11% 2.80% (2.03%)

Revenue $m

Feb May Aug Nov Year
’26 — — — — —
’21 — 0 0 0 0
’16 — — — — 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Jun Sep Dec Mar Year
’26 (3) — — — —
’26 (2) (3) (2) (2) (9)
’25 (4) (4) (4) (3) (15)
’24 (6) (2) (2) (2) (12)
’23 (5) (3) (4) (3) (16)
’22 (3) (6) (5) (3) (17)
’21 (4) (4) (4) (2) (14)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Jun Sep Dec Mar Year
’26 (3) — — — —
’26 (2) (3) (2) (2) (9)
’25 (4) (4) (4) (3) (15)
’24 (6) (2) (2) (2) (19)
’23 (5) (3) (4) (3) (21)
’22 (3) (6) (5) (3) (17)
’21 (4) (4) (4) (2) (14)
Fiscal quarters ending in the months shown.

EPS $

Jun Sep Dec Mar Year
’26 (0.91) — — — —
’26 (0.21) (0.06) (0.14) (0.07) (0.47)
’25 (0.24) (0.30) (0.36) 0.01 (0.79)
’24 (0.54) (0.43) (0.21) (0.26) (1.35)
’23 (0.60) (0.66) (0.54) (3.90) (5.70)
’22 (0.72) 0.18 (0.54) (0.55) (1.62)
’21 (2.40) (2.40) (1.54) (1.44) (8.16)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to March

Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 2027e 2028e 2029e
Price, $
Price, $ Low 40.32 20.64 36.48 8.16 6.24 2.04 1.72 1.98 1.75 1.79

Analyst estimates 2027–2029

Powerpack
High 161.28 86.40 147.84 121.92 58.56 9.54 5.04 4.97 4.68 5.18
People
People Employees 15 24 28 32 — — — 4 6 5
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.00 — — 0.00 0.00 0.00
Income, $m
Income, $m Revenue — — — — 0 — — — — —
Gross margin, % 0.00 0.00 0.00 0.00 61.22 — 0.00 — — —
EBT (8) (17) (39) (26) (20) (10) (52) (15) (13) (9)
EBT margin, % 0.00 0.00 0.00 0.00 (10,039.80) 0.00 0.00 0.00 0.00 0.00
Net income (8) (17) (39) (26) (20) (10) (42) (13) (10) (8)
Depreciation 2 2 2 2 1 — 0 0 0 0
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.08 0.00 0.00 0.00 0.00 0.00
Earnings (0.66) (36.47) (34.07) (14.48) (8.16) (1.62) (5.70) (1.35) (0.79) (0.47)
Cash flow (0.47) (26.80) (21.91) (13.02) (5.79) (2.81) (2.14) (1.29) (1.23) (0.54)
Capex 0.00 (0.97) (0.47) (0.18) (0.03) 0.00 (0.68) (0.68) 0.00 0.00
Free cash flow (0.47) (27.78) (22.38) (13.20) (5.82) (2.81) (2.82) (1.97) (1.23) (0.54)
Book value 1.47 17.61 9.76 7.37 22.52 17.63 9.14 6.48 5.51 3.87
Shares, m 11 0 1 2 2 6 7 10 12 17
Valuation, ×
Valuation, × P/E — — — — 0.00 — — — — —
P/S — — — — 356.47 — — — — —
P/B — — — — 1.28 — — — — —
EV/Sales — — — — 66.48 — — — — —
EV/FCF — — — — (0.92) — — — — —
Cash, $m
Cash, $m Operating cash flow (5) (10) (25) (23) (14) (17) (16) (12) (15) (9)
Capex (2) 0 (1) 0 0 — (5) (6) — —
Free cash flow (5) (10) (25) (23) (14) (17) (21) (19) (15) (9)
Balance, $m
Balance, $m Working capital 6 2 14 11 61 42 26 22 21 15
Total debt 1 1 1 0 0 0 0 — — —
Net debt (6) (5) (24) (14) (61) (44) (28) (23) (22) (17)
Shareholders’ equity 16 6 11 13 56 108 68 62 67 64
Returns, %
Returns, % ROA (40.36) (90.69) (143.65) (85.40) (46.13) (10.28) (40.85) (16.86) (13.17) (11.24)
ROIC 0.00 (763.15) 0.00 0.00 0.00 (15.08) (81.36) (20.74) (23.44) (14.76)
ROE (47.44) (147.88) (450.89) (212.26) (57.33) (11.98) (48.15) (19.82) (14.91) (11.94)
Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2021 · latest quarter Mar 2021

Charts ten years each

Grace Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ANVS Annovis Bio, Inc. $44.8M — (loss-making) — — n/m −329.18% (below 0%: shrinking) — 0.00% Compare
ALDX Aldeyra Therapeutics, Inc. $44.5M — (loss-making) — — n/m +46.09% (above 0%: growing) 0.00% 0.00% Compare
CELU Celularity, Inc. $43.2M — (loss-making) — (loss-making) −66.34% (below 0%: shrinking) n/m +148.35% (above 0%: growing) 62.25% (263.47%) Compare
DWTX Dogwood Therapeutics, Inc $42.5M — (loss-making) — — n/m +10.31% (above 0%: growing) — 0.00% Compare
SGMOQ Sangamo Therapeutics, Inc. $41.9M — (loss-making) — (loss-making) −77.60% (below 0%: shrinking) n/m +26.21% (above 0%: growing) 100.00% (2,215.40%) Compare
VERU Veru Inc. $41.6M — (loss-making) — (loss-making) +287.06% (above 0%: growing) n/m +0.27% (above 0%: growing) 34.92% 0.00% Compare
TIL Instil Bio, Inc. $41.6M — (loss-making) — — n/m +68.62% (above 0%: growing) 0.00% 0.00% Compare
GRCE Grace Therapeutics, Inc. $41.0M — (loss-making) — (loss-making) +5,127.27% (above 0%: growing) n/m −78.85% (below 0%: shrinking) 0.00% 0.00%
LBPS 4D pharma PLC Sponsored ADR $37.2M — (loss-making) — +41.64% (above 0%: growing) n/m −16,367.69% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $42.2M — — −12.35% — +18.26% 17.46% 0.00%

All 614 Biotechnology stocks →

Grace Therapeutics, Inc. (GRCE) key facts

  • Grace Therapeutics, Inc. (GRCE) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, GRCE traded at $1.89, a market capitalization of $41.0 million.
  • Return on equity was −11.9% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.

Grace Therapeutics, Inc. (GRCE) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/GRCE · Data as of Mar 31, 2021 · For information only; not investment advice. · © 2026 stockrow.com